Olanow, C Warren <br/><br/>
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).  [electronic resource] 

 -  Clinical neuropharmacology   
 - 58-62 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0362-5664 
<br/><br/><label>Standard No.: </label>10.1097/00002826-200403000-00003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antiparkinson Agents--adverse effects<br/>Dose-Response Relationship, Drug<br/>Dyskinesia, Drug-Induced--drug therapy<br/>Female<br/>Humans<br/>Levodopa--adverse effects<br/>Male<br/>Medical Records<br/>Organic Chemicals<br/>Parkinson Disease--drug therapy<br/>Treatment Outcome